Introduction
============

Ayurveda, or Ayurvedic medicine, is one of the oldest systems of traditional medicine (TM), with origins in India more than 3,000 years ago. Nowadays Ayurveda is popular and used worldwide in complementary and alternative healthcare and medical practices (CAM) ([@B52], [@B52]). Ayurvedic formulations are obtained using an average of 80% botanicals, 12% animals, and 8% minerals, and are used as raw materials and preparations such as extracts ([@B19]). About 7,000 plant species are used for medicinal purposes in India, from which, about 1,200 species have been reported to be actively traded ([@B14]). The total commercial demand for herbal material in India, in 2014 and 2015, was estimated to be in excess of 512,000 tons, with a market value of 1 billion USD ([@B14]). India has more than 8,000 licensed manufacturing units for medicinal products and the increasing level of consumption of herbal products exceed the supply capacity for some plant species ([@B14]). In order to ensure a level of uniformity of the therapeutic formula and the ingredients used, the Ayurvedic formulary and Ayurvedic Pharmacopeia of India was published by the Government of India as a legally binding document describing the quality, purity, and strength of selected drugs that are manufactured, distributed and sold by the licensed manufacturers in India ([@B19]).

As many other TMs, Ayurvedic herbal medicines, require quality assurances for their wider usage and acceptability in CAM practicing countries ([@B52]). The growing demand for Ayurveda encourages an industry for mass production of herbal products, leading to the use of large quantities of plant raw material, mainly harvested from the wild flora ([@B46]; [@B14]; [@B19]). Many of the Indian medicinal plant species are in short supply due to the lack of cultivation and several wild species are not available in sufficient quantities for commercial exploitation ([@B14]). The intensive use of herbal products increases the incentive for adulteration and substitution in the medicinal plant trade ([@B23]). This awareness of content irregularities calls attention to the quality of the traded mass produced herbal products with direct impact on their efficacy and safety ([@B21]). One of the pharmacognostic parameters to assure quality, safety and efficacy of a herbal medicine is the utilization of correctly identified medicinal plants used as raw material ([@B12]). Several new strategies and appropriate standard methods have been proposed to exhaustively assess and monitor both the quality of raw materials and marketed herbal products ([@B1]; [@B8]). Standard methods routinely used to assess herbal material, preparations and products rely on morphological characters, microscopy, and chemical fingerprinting \[i.e., thin--layer chromatography', high--performance liquid chromatography (HPLC), and gas chromatography (GC)\] ([@B8]; [@B26]). These methods are quick and cost-effective techniques for primary qualitative analysis of raw material and derived herbal products. Alternatively, the use of more advanced methods for identification and quantification of chemical marker compounds is becoming popular \[i.e., liquid chromatography (LC)--mass spectrometry (MS), GC-MS, and LC-nuclear magnetic resonance (NMR)\], but requires valuable instrumentation ([@B18]; [@B51]; [@B53]; [@B29]).

Various important issues influence the quality of Ayurvedic herbal products and they need to be carefully taken into consideration when determining the analytical method of choice for quality control. The herbal products are usually complex mixtures of plant material and/or extracts and excipients, and results of manifold processing steps. To apply only standard analytical methods may pose serious challenges to the accuracy of herbal product quality control. Furthermore, adulteration by the deliberate use or admixture of substitutes and undeclared plant fillers, fraudulent adulteration by using fillers of botanical origin or plant materials of inferior quality ([@B54]), the addition of pharmaceuticals or other synthetic substances in order to reach an expected effect or a certain level of marker compounds ([@B3]; [@B31]) raises concerns about the quality and safety of the herbal products. Multiple plant species as source for botanical drug as allowed in different pharmacopeias, as well as the accidental substitutions, all raise concerns ranging from simple misleading labeling to potential serious adverse drug reactions ([@B11]; [@B16]; [@B13]) or poisoning due to toxic contaminants ([@B4]).

All the standard analytical approaches, including sensory and chemical inspection may have a good resolution in quality control by detecting the quality and quantity of specific lead or phytochemical marker compounds. However, they are generally not applicable in identifying target plant species within a complex herbal product, and show low ability to detect non-targeted plant ingredients in herbal products ([@B8]). To overcome this limitation, DNA-based approaches have been proposed as useful analytical tools for the quality control of herbs and herbal products ([@B26]). DNA barcoding is a cost-effective, species-level identification based upon the use of short and standardized gene regions, known as 'barcodes' ([@B15]). Several reviews have corroborated the diverse applicability of DNA barcoding in the field of medicinal plant research ([@B43]; [@B8]). Initially used as an identification tool, DNA barcoding is now applied in the industrial quality assurance context to authenticate a wide range of herbal products ([@B8]; [@B26]; [@B34]).

The combination of High-Throughput Sequencing (HTS) and DNA barcoding, known as DNA metabarcoding, enables simultaneous high-throughput multi-taxa identification by using the extracellular and/or total DNA extracted from complex samples containing DNA of different origins ([@B42]). Several studies have utilized this approach in identifying and authenticating medicinal plants and derived herbal products. For example, *Echinacea* species, *Hypericum perforatum*, and *Veronica officinalis* were detected in 89, 68 and 15%, respectively, of the investigated herbal products ([@B27],[@B28], [@B30]). Similarly, [@B17] found that 15 tested herbal supplements contained non-listed, non-filler plant DNA, and [@B5] showed that the quality of 27 tested herbal preparations was highly affected by the presence of contaminants. [@B6] revealed the species composition of 15 highly processed traditional Chinese medicines using DNA metabarcoding, and showed that the products contained species included on CITES appendices I and II. A number of studies in India have surveyed herbal raw drug markets and tested the authenticity of the herbal drugs using DNA barcoding. These studies reported that 24% of raw drug samples of *Phyllanthus amarus* Schumach. & Thonn. were substituted with other phenotypically similar *Phyllanthus* species ([@B36]). Similar substitution were reported for other species, such as *Sida cordifolia* L. (76%) ([@B47]), *Cinnamomum verum* J.Presl (70%) ([@B40]), *Myristica fragrans* Houtt. (60%) ([@B41]), *Senna auriculata* (L.) Roxb. (50%) ([@B33]), *Senna tora* (L.) Roxb. (37%) ([@B33]) and *Senna alexandrina* Mill. (8%) ([@B33]). Furthermore, [@B48] reported that 21% of raw drugs in Indian herbal markets were unauthentic. [@B35] found that 60% of 93 herbal products sold in the form of capsules and plant powders in local stores in India were adulterated. Studies that combined spectroscopic methods, such as NMR, with DNA barcoding or microscopy to authenticate herbal products, reported 80% adulteration in *Saraca asoca* ([@B45]), 80% in *Berberis aristata* ([@B37]) and 22% in *Piper nigrum* ([@B25]). All these studies utilizing DNA barcoding and metabarcoding have highlighted the concerns over the quality and good labeling practices of herbal products ([@B6]; [@B17]; [@B27],[@B28]; [@B50]).

The aim of this study was threefold. First, we aimed to test the composition and fidelity of Ayurvedic products marketed in Europe using DNA metabarcoding. Secondly, we aimed to analyze the presence of any red listed species listed on the product label and used as ingredients using DNA metabarcoding. Our final aim was to evaluate the ability of DNA metabarcoding to identify the presence of authentic species, any substitution and adulteration and/or presence of other off labeled plant species.

Materials and Methods {#s1}
=====================

Sample Collection
-----------------

Seventy-nine Ayurvedic herbal products sold as tablets (*n* = 30), capsules (*n* = 30), powders (*n* = 16), and extracts (*n* = 3) were purchased via e-commerce (*n* = 53) and pharmacies (*n* = 26), from Norway (*n* = 21), Romania (*n* = 26), and Sweden (*n* = 32). Based on the label information, 26 were single plant ingredient products, 39 contained between two to ten plant ingredients, and 14 products contained between eleven to 27 plant ingredients ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). The products contained a total of 159 plant species belonging to 132 genera and 60 families ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). It was also confirmed that nrITS sequences of all the 159 plant species labeled in the analyzed herbal products were available within the NCBI/GenBank database ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). The accepted binomial names and authors of the plants species used as ingredients were validated using [@B44]. The Ayurvedic herbal products were imported into Norway for scientific analyses under Norwegian Medicines Agency license no. 16/04551--2. An overview of the products, including label information, but not the producer/importer name, lot number, expiration date or any other information that could lead to the identification of that specific product, can be found in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}.

DNA Extraction, Amplicon Generation, and High Throughput Sequencing
-------------------------------------------------------------------

The 79 Ayurvedic herbal products were processed depending on their pharmaceutical formulation, in addition to an extraction blank per DNA extraction round. A small amount of each herbal product, about 200 mg, was homogenized using 3--5 zirconium grinding beads in a Mini-Beadbeater-1 (Biospec Products Inc., Bartlesville, Oklahoma, United States). The total DNA from each product was extracted from homogenized contents using CTAB extraction ([@B9]). The final elution volume was 100 μl. Extracted DNA was quantified using a Qubit 2.0 Fluorometer and Qubit dsDNA HS Assay Kit (Invitrogen, Carlsbad, California, United States). All amplicon libraries, defined as PCR amplified products from a study sample, were prepared in three replicates. For each replicate two nuclear ribosomal target sequences were amplified, the internal transcribed spacers nrITS1 and nrITS2, respectively. The fusion primers included the annealing motif from the [@B39] plant-specific primer pairs 17SE and 5.8I1, and 5.8I2 and 26SE. The forward primers included the Ion Torrent A adapter, a 10 bp multiplex identifier tag following the IonXpress setup for Ion Torrent (Thermo Fisher Scientific, Carlsbad, California, United States). The reverse primer included the truncated P1 (trP1) tags in addition to the annealing motif. Expected amplicon sizes were 300--350 bp.

Polymerase chain reactions were carried out using DNA extracted from the herbal products in final reaction volumes of 25 μl including 0.5 μl of template DNA solution (ranging from 0.5 to 2 ng/μl), 1X Q5 reaction buffer (New England Biolabs Inc., United Kingdom), 0.6 μM of each primer (Biolegio B.V., Netherlands), 200 nM dNTPs, 5 U Q5 High-Fidelity DNA Polymerase (New England Biolabs Inc., United Kingdom) and 1X Q5 High GC enhancer. The PCR cycling protocol consisted of initial denaturation at 98°C for 30 s, followed by 35 cycles of denaturation at 98°C for 10 s, annealing at 56°C for nrITS1 or 71°C for nrITS2 for 30 s, and elongation at 72°C for 30 s, followed by a final elongation step at 72°C for 2 min. Three PCR negative controls of the extraction blanks were included per amplification to control for external and cross sample contamination. After PCR, the amplicons were purified using Illustra Exostar (GE Healthcare, Chicago, Illinois, United States) in accordance with the manufacturer protocols. The molarity of each amplicon library was measured using a qPCR based assay (CFX96 Touch Real-Time PCR Detection System, Bio-Rad, Hercules, California, United States). The equimolar amounts of each amplicon library were merged and sequenced using an Ion Torrent Personal Genomic Machine (Thermo Fisher Scientific) as described by [@B27].

Bioinformatics Analysis
-----------------------

The sequencing read data were analyzed and demultiplexed into FASTQ files, per sample, using Torrent Suite version 5.0.4 (LT), and each of the replicates was analyzed individually. FASTQ read files were processed using the HTS-barcode-checker pipeline available as a Galaxy pipeline at the Naturalis Biodiversity Center^[1](#fn01){ref-type="fn"}^ ([@B20]). Using the HTS pipeline, nrITS1 and nrITS2 primer sequences were used to demultiplex the sequencing reads per sample and to filter out reads that did not match any of the primers. PRINSEQ was used to determine filtering and trimming values based on read lengths and Phred read quality. All reads with a mean Phred quality score of less than 26 were filtered out, as well as reads with a length of less than 200 bp. The remaining reads were trimmed to a maximum length of 380 bp. CD-HIT-EST was used to cluster reads into molecular operational taxonomic units (MOTUs) defined by a sequence similarity of \>99% and a minimum number of ten reads. The consensus sequences of non-singleton MOTUs were queried using BLAST against a reference nucleotide sequence database, with a maximum e-value of 0.05, a minimum hit length of 100 bp and sequence identity of \>97%. The number of reads per MOTU, as well as the BLAST results per MOTU, were compiled using custom scripts from the HTS Barcode Checker pipeline ([@B20]). The reference sequence database consisted of a local copy of the NCBI/GenBank nucleotide database that is refreshed monthly. These parameters were applied to each of the replicates. A species was considered and validated as being present within the product only if this was detected in at least 2 out of the 3 replicates.

Presence and Abundance of Species Across Samples
------------------------------------------------

To assess species diversity within each sample, and to obtain insights into the dominant species within the Ayurvedic herbal products, the read abundances were normalized by dividing the number of reads for a MOTU by the total number of reads per sample. As a result, the read counts are transformed into a proportion of reads found per species within each sample ([Supplementary Tables S3](#SM3){ref-type="supplementary-material"}, [S4](#SM4){ref-type="supplementary-material"}). Furthermore, MOTUs detected in at least two out of the three replicates, for each sample, were categorized into expected-detected (MOTUs corresponding to species listed on the product label versus species detected in the analysis), expected-not detected (MOTUs corresponding to species listed on the product label but not detected in the analysis), and not expected-detected (MOTUs corresponding to species non-listed on the product label but detected in the analysis) ([Supplementary Table S5](#SM5){ref-type="supplementary-material"}). The total occurrences of MOTUs per category of expected and detected were evaluated ([Supplementary Table S5](#SM5){ref-type="supplementary-material"}), and a matrix of correlation was generated using ClustVis ([@B22]).

Results
=======

Fidelity of Ayurvedic Products
------------------------------

The genomic DNA extracts were highly variable in quantity and quality. Total DNA concentration for each of the 79 herbal products is provided in [Supplementary Table S6](#SM6){ref-type="supplementary-material"}. [Table 1](#T1){ref-type="table"} shows the average DNA yield for each of the investigated herbal product types. The result shows that three samples labeled as containing only standardized extracts yielded an average of 0.5 ng/μl DNA, whereas tablets, capsules and powders yielded an average of 5.8, 9.6, and 44.7 ng/μl DNA, respectively. Out of 79 products used in the study, 10 tablets were also labeled to contain extracts in addition to crude plant material (\#6, \#12, \#13, \#14, \#17, \#18, \#20, \#21, \#38, and \#74). PCR amplification for nrITS1 and nrITS2 regions were performed for all 79 samples, and amplicons were generated for all replicates for nrITS1 and nrITS2 (for samples and concentrations see [Supplementary Table S6](#SM6){ref-type="supplementary-material"}). The extraction blanks yielded no molecular operational taxonomic units (MOTUs) with nrITS1 and nrITS2 primers.

###### 

Genomic DNA yield and amplicon concentrations per herbal product type.

  Product type   No. of herbal products   Average genomic DNA concentration (ng/μl) (SD)   Average amplicon concentration quantified by qPCR (ng/μl)   No. of products yielding DNA sequences   No. of products analyzed post filtering                                           
  -------------- ------------------------ ------------------------------------------------ ----------------------------------------------------------- ---------------------------------------- ----------------------------------------- ----------- ---------- ----------- ---- ----
  Tablets        30                       5.8 (6)                                          5.0 (7)                                                     4.3 (4)                                  7.7 (15)                                  7.1 (10)    4.9 (4)    15.3 (18)   20   19
  Capsules       30                       9.6 (12)                                         6.2 (11)                                                    6.0 (11)                                 5.1 (9)                                   5.8 (9)     4.2 (5)    8.3 (13)    16   15
  Powders        16                       44.7 (63)                                        19.2 (25)                                                   3.4 (6)                                  2.4 (3)                                   9.4 (19)    4.0 (11)   8.3 (18)    5    5
  Extracts       3                        0.5 (0.5)                                        3.4 (0.4)                                                   2.4 (2)                                  2.4 (2)                                   20.3 (13)   8.5 (4)    21 (19)     3    \-
                                                                                                                                                                                                                                                                                  

The sequencing success rate was 44% for ITS1 and 41% for ITS2 ([Supplementary Table S6](#SM6){ref-type="supplementary-material"}). Thirty-five products out of 79 (44%) yielded no MOTUs in any of the replicates either for nrITS1 or nrITS2 that fulfilled our quality criteria, and they were excluded from the results and the further discussion (\#11, \#20--22, \#28, \#29, \#33, \#35, \#37--39, \#41--51, \#53, \#54, \#56, \#57, \#59, \#62, 64, \#65, \#67, \#71, \#72, \#76, and \#78). These products consisted of 13 tablets, 11 capsules, and 11 powders ([Supplementary Table S6](#SM6){ref-type="supplementary-material"}). The products that yielded MOTUs were represented by 17 tablets, 19 capsules, 5 powders, and 3 extracts ([Supplementary Table S7](#SM7){ref-type="supplementary-material"}).

A total of 188 different plant species belonging to 154 genera and 65 families were identified from the retained MOTUs using BLAST. The separate analyses resulted in 131 plant species (110 genus and 53 families) for nrITS1, and 101 plant species (84 genus and 39 families) for nrITS2. The number of species detected per sample ranged from one to 42. After applying our quality selection criteria, where a species was considered and validated as being present within the product only if it was detected in at least 2 out of the 3 replicates, five additional products (\#4, \#15, \#24, \#25, and \#26 includes 2 tablets and 3 extracts) that failed to yield the same MOTU in any of the replicates were discarded. The remaining 39 products resulted in a total of 97 plant species belonging to 40 families (62 species for nrITS1, and 60 species for nrITS2). The species detected for all the replicates for both ITS1 and ITS2, were merged for each sample for further analyses ([Figure 1](#F1){ref-type="fig"} and [Supplementary Tables S3](#SM3){ref-type="supplementary-material"}, [S7](#SM7){ref-type="supplementary-material"}).

![Discrepancies between listed species and detected species using DNA metabarcoding in Ayurvedic herbal products. **(A)** Total number of occurrences of expected species as labeled in the herbal products and detected species using DNA metabarcoding. **(B)** Total number of detected species occurred among expected species as labeled in herbal products (expected-detected), the number of undetected species among the expected species as labeled (expected-not detected), and the number of detected unexpected species (not expected-detected) found in herbal products using DNA metabarcoding. The overlapping numbers are the same species detected in herbal products as expected, detected and unexpected detected.](fpls-10-00068-g001){#F1}

[Figure 2](#F2){ref-type="fig"} illustrates the fidelity of herbal products between various product forms, country, and method of acquisition. In ten out of twelve single ingredient products that were labeled as containing only one species, we detected multiple species (exceptions \#5 and \#52), from which six contained the species labeled on the product together with other species, whereas four products did not contained the species listed on the product label but contained several other non-listed species. Out of 27 successfully analyzed multiple ingredient products, 8 (29.6%) products contained none of the species listed on the label, and the remaining 19 products contained between one to five species listed on the label along with many other species not specified on the product label. The fidelity rate for single ingredient products was 67% (8 out of 12), and the overall ingredient fidelity (detected species from product label/total number of species on label) for multi ingredient products was 21% and for all products 24%. [Table 2](#T2){ref-type="table"} shows the top ten products with highest fidelity is also relatively high in the level of substitution, whereas [Table 3](#T3){ref-type="table"} shows the top ten products with highest adulteration and its fidelity.

![Fidelity of herbal products **(A)** per product form; **(B)** per country; **(C)** per acquisition method. *n* = total number of herbal products.](fpls-10-00068-g002){#F2}

###### 

Top ten products with the highest fidelity and their level of adulteration.

  Herbal product code   Product type   No. species on label   Detected by DNA metabarcoding   Fidelity (Expected-detected, absolute)   Fidelity (Expected-detected, relative)   Adulteration (Detected-Not expected, absolute)   Adulteration (Detected-Not expected, relative)
  --------------------- -------------- ---------------------- ------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------------------------ ------------------------------------------------
  34                    Tablets        8                      15                              5                                        63%                                      10                                               67%
  31                    Tablets        10                     7                               5                                        50%                                      2                                                29%
  36                    Tablets        13                     7                               4                                        31%                                      3                                                43%
  73                    Tablets        14                     14                              3                                        21%                                      11                                               79%
  74                    Tablets        9                      5                               3                                        33%                                      2                                                40%
  66                    Capsules       6                      5                               3                                        50%                                      2                                                40%
  7                     Capsules       6                      5                               2                                        33%                                      3                                                60%
  75                    Tablets        3                      3                               2                                        67%                                      1                                                33%
  69                    Capsules       1                      13                              1                                        100%                                     12                                               92%
  3                     Tablets        4                      9                               1                                        25%                                      8                                                89%
                                                                                                                                                                                                                                 

###### 

Top ten products with the highest adulteration and their fidelity.

  Herbal product code   Product type   No species on label   Detected by DNA metabarcoding   Fidelity (Expected-detected, absolute)   Fidelity (Expected-detected, relative)   Adulteration (Detected-Not expected, absolute)   Adulteration (Detected-Not expected, relative)
  --------------------- -------------- --------------------- ------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------------------------ ------------------------------------------------
  69                    Capsules       1                     13                              1                                        100%                                     12                                               92%
  32                    Tablets        6                     12                              0                                        0%                                       12                                               100%
  73                    Tablets        14                    14                              3                                        21%                                      11                                               79%
  34                    Tablets        8                     15                              5                                        63%                                      10                                               67%
  3                     Tablets        4                     9                               1                                        25%                                      8                                                89%
  68                    Capsules       1                     8                               0                                        0%                                       8                                                100%
  40                    Capsules       4                     8                               1                                        25%                                      7                                                88%
  27                    Capsules       1                     8                               1                                        100%                                     7                                                88%
  6                     Tablets        9                     7                               1                                        11%                                      6                                                86%
  23                    Tablets        4                     7                               1                                        25%                                      6                                                86%
                                                                                                                                                                                                                                

[Figure 3](#F3){ref-type="fig"} depicts all 97 detected species based on the relative abundance of read numbers in 39 herbal products per type under the categories of expected-detected, expected-not detected, and not expected-detected.

![Detection of species in Ayurvedic herbal products. Species (y-axis) are colored by relative abundance of normalized read numbers. Species are categorized in expected-detected and not expected-detected, based on the total number of occurrences, whereas the category expected-not detected is based on the number of times that the species is expected but not detected. Species are clustered by Euclidean distances. Ayurvedic samples (x-axis) are numbered with product code and grouped by product type.](fpls-10-00068-g003){#F3}

Plant Ingredients in Herbal Products
------------------------------------

A total of 159 plant species belonging to 132 genera and 60 families were specified on the labels of the 79 Ayurvedic herbal products used in this study. Assessing the source and availability of these plants, we found that 83 plants species are solely harvested from wild, and 31 of these are under various threat levels, including critically endangered and protected species, such as *Pterocarpus marsupium* Roxb., *Pterocarpus santalinus* L.f., *Santalum album* L., and *Saraca asoca* (Roxb.) Willd. ([Figure 4](#F4){ref-type="fig"} and [Supplementary Table S2](#SM2){ref-type="supplementary-material"}; [@B49]; [@B10]; [@B14]). The DNA metabarcoding analysis confirms the presence of four of these threatened species, i.e., *Celastrus paniculatus*, *Glycyrrhiza glabra, Gymnema sylvestre,* and *Saraca asoca*, whereas the remaining threatened species were not detected despite being included as labeled ingredients ([Figure 3](#F3){ref-type="fig"} and [Supplementary Table S7](#SM7){ref-type="supplementary-material"}). The following species were found in over 20% of the products: *Withania somnifera* (L.) Dunal (39%), *Tribulus terrestris* L. (27%), *Convolvulus prostratus* Forssk. (23%), *Coriandrum sativum* L. (23%), *Ipomoea parasitica* (Kunth) G. Don (23%), *Ocimum basilicum* L. (23%) and *Senna alexandrina* Mill. (23%) ([Figure 3](#F3){ref-type="fig"} and [Supplementary Table S3](#SM3){ref-type="supplementary-material"}). Seventeen are present in more than 10% of samples are listed in the [Supplementary Table S3](#SM3){ref-type="supplementary-material"}.

![Source and conservation status of species in Ayurvedic products. **(A)** Source of plants labeled as ingredients in the herbal products studied. **(B)** Conservation status of plants labeled as ingredients in the herbal products studied. *N* = total number of species. ^∗^Wild/Cultivation denotes that the plants species are sourced both from wild and cultivation.](fpls-10-00068-g004){#F4}

Discussion
==========

The British Pharmacopeia is one the first to publish a specific methods section on DNA barcoding, and in the 2016 version it included a new methods appendix on "Deoxyribonucleic acid (DNA) based identification techniques for herbal drugs" to create a framework for compliance of DNA barcoding with regulatory requirements ([@B2]; [@B34]). However, DNA barcoding and metabarcoding are not yet widespread validated methods for use in the regulatory context of quality control. Several studies advocate its usefulness for herbal product authentication and pharmacovigilance either as a standard method or as a complementary method ([@B17]; [@B27],[@B28], [@B29]; [@B34]). In this study, DNA metabarcoding was used as an analytical approach in Ayurveda herbal product authentication.

A number of studies have shown that the quality of the extraction substrate influences amplification and sequencing success ([@B17]; [@B27], [@B30]). In addition the presence of DNA in the extraction substrates is influenced by degradation during the harvesting, drying, storage, and industrial processing of plant material ([@B24]). The success rate in generating raw sequence reads from the herbal products, and the number of products from which MOTUs could be identified per product after applying strict trimming and filtering quality criteria, reduced the number of samples yielding DNA metabarcoding results from 79 to 39 samples. In this study, 44% of products did not yield MOTUs in any of the replicates either for nrITS1 or nrITS2. Also, in the herbal products labeled to contain only extracts, no plant DNA was detected. The undetected MOTUs in these products could be related to the methodological framework of DNA metabarcoding such as DNA extraction protocol, suitability of primer pair sequences, amplification protocols in PCR for the library preparation, sequencing platform, filtering, quality thresholds, and chimera removal, and clustering thresholds ([@B7]; [@B34]; [@B30]). In addition, extraction of crude herbal drugs either in pre-processing or manufacturing can reduce the availability of plant DNA from those species, especially if material is extracted in boiling water or alcohol, and evaporated or dried at high temperatures.

Considerable incongruences were observed between the detected species and those listed on the label of the products. Similarly, [@B28] demonstrated the ability of DNA metabarcoding in detecting *Hypericum* species in complex herbal formulations, and revealed the incongruence between constituent species and those listed on the label in all products. Also, [@B7] performed DNA metabarcoding analyses on 55 commercial products based on orchids (*salep*) purchased in Iran, Turkey, Greece, and Germany, and concluded that there are significant differences in labeled and detected species. They also highlighted the applicability of DNA metabarcoding in targeted efforts for conservation of endangered orchid species. In our study, we detected a total of 97 species in 39 products that passed our quality criteria, and most of the identified species are likely ingredients of Ayurvedic herbal products. Detection of certain species is improbable given their distribution or unlikely use, and these include *Achillea millefolium* L., *Anchusa italica* Retz., *Calluna vulgaris* (L.) Hull, *Damrongia cyanantha* Triboun, *Fraxinus albicans* Buckley and *Trigastrotheca molluginea* F.Muell. The identification of these plant species may be explained by *(i)* amplified PCR chimeras; *(ii)* false-positive BLAST identifications due to incomplete or error-prone reference databases; or *(iii)* presence of pollen from wind pollinating species, and this confirms previously raised concerns about the hypersensitivity of DNA metabarcoding ([@B7]).

Out of 97 species detected in the DNA metabarcoding analysis, 40 species are sourced from wild, 38 species are cultivated, and 15 species are sourced from both wild and cultivation. Similarly, among the 89 species which were not detected in the analysis, 62 species are mainly sourced from wild, including endangered species such as *Embelia ribes* Burm.f., *Pterocarpus marsupium* Roxb., *Pterocarpus santalinus* L.f., *Pueraria tuberosa* (Willd.) DC., and *Santalum album* L. Understanding, the discrepancies between the species detected using DNA metabarcoding and those listed on the label of the products require careful consideration. In DNA metabarcoding analyses, the level of similarity clustering thresholds (\>97, \>99, and 100%) have an impact on the number and size of assigned MOTUs ([@B27]). In this study, we used a 99% clustering threshold similar to previously published studies ([@B27]; [@B50]). Furthermore, to limit the impact of sequencing errors, which are known to affect the Ion Torrent sequencing platform ([@B32]) and which could lead to the formation of false MOTUs, we used only the clusters that contained a minimum of 10 reads. In addition, by using three replicates for each sample and marker, we reduced further noise by accepting MOTUs only if present in more than one replicate. Furthermore, the strict filtering and trimming thresholds for base calling, length and quality, and strict clustering criteria for MOTUs formation, increase confidence of the results. As reported by previous studies ([@B17]; [@B28]), the results related to the authentication of herbal products using DNA metabarcoding need to focus primarily on checking the presence of the labeled ingredients and contaminants. The presence of non-listed species may be explained by various factors, including but not limited to the deliberate adulteration and unintentional substitution that may occur from the early stage of the supply chain of medicinal plants (i.e., cultivation, transport, and storage), to the manufacturing process and the commercialization of the final products. DNA metabarcoding is a highly sensitive method and even traces of DNA, e.g., contamination from grains of pollinating species or plant dust in the manufacturing process, can be detected and identified.

The advantage of DNA metabarcoding is its ability to simultaneously identify total species diversity within complex multi-ingredient and processed mixtures. Importantly, DNA metabarcoding data is used for qualitative evaluation only, to determine presence of taxa, and not for quantitative assessment of relative species abundance based on read numbers, as many variables considerably impact the obtained sequence read results ([@B38]). In the context of the quality control of herbal products, DNA metabarcoding does not provide any quantitative nor qualitative information of the active metabolites in the raw plant material or the resulting preparation, and this narrows its applicability only to identification and authentication procedures. Thus, if product safety control relies on threshold levels of specific marker compounds, absence of toxins, allergens and admixed pharmaceuticals, then other methods may be more relevant than DNA-based composition analysis. On the other hand, if product fidelity, species substitution or adulteration is suspected then the latter method outperforms in terms of resolution.

The results of this study reveal that there is a need for a better quality control of herbal products. A novel analytical approach should eventually use a combination of innovative high throughput methods that complement the standard ones recommended today.

Conclusion
==========

Assessment of Ayurvedic herbal medicines using DNA metabarcoding provides insight into species diversity in these products and highlights a marked incongruence between species listed as ingredients on the product labels and those detected from DNA present in the samples. Detection of not-listed and not-expected species first and foremost suggests irregularities in the manufacturing process. The presence of foreign plant material could be due accidental reasons, such as contamination from insufficiently cleaned bags, containers, mills, conveyors, and other equipment, or co-occurrence of weeds in cultivation, pollen from wind pollinated species or seeds from wind-dispersed species. However, foreign plant material could also result from fraud, i.e., substitution, adulteration and/or admixture of other species. Interpretation of incongruences should focus on the detected species in the products, and less on the failure to detect species as there are many steps in manufacturing processes that could lead to degradation or loss of DNA beyond detectable limits, e.g., alcoholic extraction, decoction and drying of material at high temperatures. Our study showed that the investigated herbal products contained species not listed on the product labels, and this reveals a clear need for improved quality control. A novel analytical approach should eventually use a combination of advanced chemical methods and innovative high throughput sequencing to complement the standard ones recommended today. The findings of our study show that DNA metabarocoding is a promising tool for quality evaluation of herbal products and pharmacovigilance, and a good candidate for an effective use as a regulatory tool to authenticate complex herbal products. However, standardization of protocols is necessary before DNA metabarcoding can be implemented as a routine analytical approach and approved by competent authorities for use in a regulatory framework.
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